- Home
- AZN vs MRK Comparison
AZN vs MRK Comparison
Compare AZN & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AZN
- MRK
- Stock Information
- Founded
- AZN 1992
- MRK 2000
- Country
- AZN United Kingdom
- MRK United States
- Employees
- AZN N/A
- MRK N/A
- Industry
- AZN Biotechnology: Pharmaceutical Preparations
- MRK Biotechnology: Pharmaceutical Preparations
- Sector
- AZN Health Care
- MRK Health Care
- Exchange
- AZN Nasdaq
- MRK Nasdaq
- Market Cap
- AZN 228.9B
- MRK 218.2B
- IPO Year
- AZN 1993
- MRK N/A
- Fundamental
- Price
- AZN $69.95
- MRK $79.11
- Analyst Decision
- AZN Strong Buy
- MRK Buy
- Analyst Count
- AZN 3
- MRK 15
- Target Price
- AZN $95.00
- MRK $113.71
- AVG Volume (30 Days)
- AZN 4.0M
- MRK 13.9M
- Earning Date
- AZN 07-24-2025
- MRK 07-29-2025
- Dividend Yield
- AZN 2.21%
- MRK 4.10%
- EPS Growth
- AZN 22.71
- MRK 667.14
- EPS
- AZN 4.97
- MRK 6.88
- Revenue
- AZN $54,982,000,000.00
- MRK $63,922,000,000.00
- Revenue This Year
- AZN $9.56
- MRK $2.42
- Revenue Next Year
- AZN $6.09
- MRK $5.76
- P/E Ratio
- AZN $14.05
- MRK $11.50
- Revenue Growth
- AZN 15.48
- MRK 4.10
- 52 Week Low
- AZN $61.24
- MRK $73.31
- 52 Week High
- AZN $87.68
- MRK $134.63
- Technical
- Relative Strength Index (RSI)
- AZN 42.41
- MRK 49.58
- Support Level
- AZN $72.18
- MRK $77.10
- Resistance Level
- AZN $75.38
- MRK $82.44
- Average True Range (ATR)
- AZN 1.03
- MRK 1.82
- MACD
- AZN -0.36
- MRK 0.19
- Stochastic Oscillator
- AZN 5.07
- MRK 52.63
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
About MRK Merck & Company Inc. (new)
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.